These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 7432317)
61. Comparative effects of calcipotriol ointment (50 micrograms/g) and 5% coal tar/2% allantoin/0.5% hydrocortisone cream in treating plaque psoriasis. Pinheiro N Br J Clin Pract; 1997; 51(1):16-9. PubMed ID: 9158266 [TBL] [Abstract][Full Text] [Related]
62. Intolerance and contact allergy to tar and dithranol in psoriasis. Burden AD; Muston H; Beck MH Contact Dermatitis; 1994 Sep; 31(3):185-6. PubMed ID: 7821017 [No Abstract] [Full Text] [Related]
63. New chemical stabilizers, vehicles and delivery systems to enhance efficacy of low strength anthralin formulations. van Scott EJ; Yu RJ Br J Dermatol; 1981 Aug; 105 Suppl 20():35-8. PubMed ID: 7284262 [No Abstract] [Full Text] [Related]
68. [Glucose-6-phosphate dehydrogenase and topical antipsoriatics. A comparison of anthralin, anthralin-monoacetate, anthralin-diacetate, anthralin-triacetate and 6-hydroxy-2-oxobenzoxathiole (author's transl)]. Raab W; Siber H Arch Dermatol Forsch; 1974; 249(2):179-89. PubMed ID: 4418435 [No Abstract] [Full Text] [Related]
69. Topical tazarotene vs. coal tar in stable plaque psoriasis. Kumar U; Kaur I; Dogra S; De D; Kumar B Clin Exp Dermatol; 2010 Jul; 35(5):482-6. PubMed ID: 19874376 [TBL] [Abstract][Full Text] [Related]
70. Anthralin: historical and current perspectives. Ashton RE; Andre P; Lowe NJ; Whitefield M J Am Acad Dermatol; 1983 Aug; 9(2):173-92. PubMed ID: 6309924 [TBL] [Abstract][Full Text] [Related]
71. A topical treatment program for psoriasis with low anthralin concentrations. Brody I; Johansson A J Cutan Pathol; 1977 Oct; 4(5):233-43. PubMed ID: 342554 [TBL] [Abstract][Full Text] [Related]
72. An update on topical therapies for mild-moderate psoriasis. van de Kerkhof PC Dermatol Clin; 2015 Jan; 33(1):73-7. PubMed ID: 25412784 [TBL] [Abstract][Full Text] [Related]
73. In search for new antipsoriatic agents: NAD topical composition. Wozniacka A; Szajerski P; Adamus J; Gebicki J; Sysa-Jedrzejowska A Skin Pharmacol Physiol; 2007; 20(1):37-42. PubMed ID: 17035720 [TBL] [Abstract][Full Text] [Related]
74. Factors affecting the clearance of psoriasis with dithranol (anthralin). Comaish S; Smith J; Seville RH Br J Dermatol; 1971 Mar; 84(3):282-9. PubMed ID: 5572679 [No Abstract] [Full Text] [Related]
75. [Antipsoriatic effect of dithranol (anthralin). 1]. Raab W Hautarzt; 1975 Sep; 26(9):452-5. PubMed ID: 1184389 [TBL] [Abstract][Full Text] [Related]
76. [Treatment of psoriasis with salicylic acid, tar and dithranol]. Juhlin L Lakartidningen; 1979 Oct; 76(43):3758-9. PubMed ID: 529922 [No Abstract] [Full Text] [Related]
77. Woronoff ring during anthralin therapy for psoriasis. Gupta AK; Ellis CN; Goldfarb MT; Voorhees JJ Arch Dermatol; 1986 Mar; 122(3):248. PubMed ID: 3954390 [No Abstract] [Full Text] [Related]
78. On the stability of some antipsoriatic active anthralin (dithranol) derivatives. Schaltegger A; Bloch U; Krebs A Dermatologica; 1982 Oct; 165(4):363-8. PubMed ID: 7152072 [No Abstract] [Full Text] [Related]